Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Holdings
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Quarterly results
Acq. announced
CC transcript
Appointed director
Inv. presentation

Altimmune, Inc. (PIP) Create: Alert

All | News | Filings
Date FiledTypeDescription
09/29/2023 4 Drutz David (Director) has filed a Form 4 on Altimmune, Inc.
Txns: Granted 26,100 options to buy @ $2.5, valued at $65.3k
09/29/2023 4 Hodges Philip (Director) has filed a Form 4 on Altimmune, Inc.
Txns: Granted 26,100 options to buy @ $2.5, valued at $65.3k
09/29/2023 4 Sohn Catherine A. (Director) has filed a Form 4 on Altimmune, Inc.
Txns: Granted 26,100 options to buy @ $2.5, valued at $65.3k
09/29/2023 4 GILL JOHN (Director) has filed a Form 4 on Altimmune, Inc.
Txns: Granted 26,100 options to buy @ $2.5, valued at $65.3k
09/29/2023 4 SAYARE MITCHEL (Director) has filed a Form 4 on Altimmune, Inc.
Txns: Granted 26,100 options to buy @ $2.5, valued at $65.3k
09/29/2023 4 Jorkasky Diane (Director) has filed a Form 4 on Altimmune, Inc.
Txns: Granted 26,100 options to buy @ $2.5, valued at $65.3k
09/28/2023 8-K Quarterly results
08/16/2023 ARS Form ARS - Annual Report to Security Holders:
08/16/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
08/15/2023 4 Drutz David (Director) has filed a Form 4 on Altimmune, Inc.
Txns: Bought 300 shares @ $2.875, valued at $862.5
08/10/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/10/2023 8-K Quarterly results
Docs: "Altimmune Announces Second Quarter 2023 Financial Results and Provides"
08/02/2023 4 Garg Vipin K (President and CEO) has filed a Form 4 on Altimmune, Inc.
Txns: Granted 126 shares @ $2.81, valued at $354.1
08/02/2023 4 Eisenstadt Richard I (CFO) has filed a Form 4 on Altimmune, Inc.
Txns: Granted 1,825 shares @ $2.81, valued at $5.1k
08/02/2023 4 Harris Matthew Scott (Chief Medical Officer) has filed a Form 4 on Altimmune, Inc.
Txns: Granted 691 shares @ $2.81, valued at $1.9k
08/02/2023 4 Roberts M Scot (Chief Scientific Officer) has filed a Form 4 on Altimmune, Inc.
Txns: Granted 568 shares @ $2.81, valued at $1.6k
08/02/2023 4 Jordt Raymond M (Chief Business Officer) has filed a Form 4 on Altimmune, Inc.
Txns: Granted 1,832 shares @ $2.81, valued at $5.1k
07/10/2023 SC 13G/A STATE STREET CORP reports a 1.6% stake in EXIT FILING ALTIMMUNE INC
07/06/2023 4 GILL JOHN (Director) has filed a Form 4 on Altimmune, Inc.
Txns: Sold 2,714 shares @ $15, valued at $40.7k
05/11/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/11/2023 8-K Quarterly results
Docs: "Altimmune Announces First Quarter 2023 Financial Results and Provides"
03/27/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
03/27/2023 4 Sohn Catherine A. (Director) has filed a Form 4 on Altimmune, Inc.
Txns: Granted 47,000 options to buy @ $4.19, valued at $196.9k
03/27/2023 3 Sohn Catherine A. (Director) has filed a Form 3 on Altimmune, Inc.
03/27/2023 8-K Appointed a new director
Docs: "Altimmune Appoints Former GSK Executive Catherine Angell Sohn, Pharm.D. to"
03/24/2023 4 Eisenstadt Richard I (CFO) has filed a Form 4 on Altimmune, Inc.
Txns: Bought 10,000 shares @ $4.314, valued at $43.1k
03/23/2023 4 Harris Matthew Scott (Chief Medical Officer) has filed a Form 4 on Altimmune, Inc.
Txns: Bought 10,000 shares @ $4.22, valued at $42.2k
03/21/2023 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "MOMENTUM Phase 2 Obesity Trial",
"Slide Presentation of Altimmune, Inc."
02/28/2023 S-3ASR Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers:
02/28/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
02/28/2023 8-K Quarterly results
Docs: "Altimmune Announces Fourth Quarter and Full Year 2022 Financial Results and Provides"
02/14/2023 SC 13G/A TANG CAPITAL PARTNERS LP reports a 5.5% stake in Altimmune, Inc.
02/14/2023 SC 13G/A Avidity Partners Management LP reports a 8.1% stake in Altimmune Inc.
02/14/2023 SC 13G/A Cormorant Asset Management, LP reports a 5.3% stake in Altimmune, Inc.
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy